EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+41.69%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$361M
AUM Growth
+$361M
(+19%)
Cap. Flow
-$26.5M
Cap. Flow
% of AUM
-7.33%
Top 10 Holdings %
Top 10 Hldgs %
83.89%
Holding
44
New
13
Increased
6
Reduced
5
Closed
11
Top Buys
| 1 |
CytomX Therapeutics
CTMX
|
$13.7M |
| 2 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
$12.4M |
| 3 |
Fate Therapeutics
FATE
|
$11.5M |
| 4 |
Aclaris Therapeutics
ACRS
|
$7.73M |
| 5 |
Tempest Therapeutics
TPST
|
$6.57M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$19.8M |
| 2 |
Ardelyx
ARDX
|
$18.6M |
| 3 |
FibroGen
FGEN
|
$15.9M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$15M |
| 5 |
Editas Medicine
EDIT
|
$10.2M |
Sector Composition
| 1 | Healthcare | 92.37% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Assembly Biosciences
ASMB
$190M
| $75M | 18.97% | 2,943,164 | – | – |
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $49.6M | 12.53% | 2,905,515 +50,000 | +2% | +$853K |
|
3
Galapagos
GLPG
$2.07B
| $47.5M | 12.01% | 551,041 -10,300 | -2% | -$888K |
|
4
Ascendis Pharma
ASND
$11.8B
| $28.7M | 7.26% | 1,025,700 +50,000 | +5% | +$1.4M |
|
5
Kura Oncology
KURA
$686M
| $23M | 5.81% | 2,611,906 | – | – |
|
|
6
Aclaris Therapeutics
ACRS
$209M
| $20.1M | 5.07% | 673,100 +259,100 | +63% | +$7.73M |
|
|
7
CytomX Therapeutics
CTMX
$336M
| $13.7M | 3.47% | +794,969 | New | +$13.7M |
|
|
CASC
8
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $12.4M | 3.14% | +3,000,000 | New | +$12.4M |
|
|
9
Fate Therapeutics
FATE
$120M
| $11.5M | 2.92% | +2,537,026 | New | +$11.5M |
|
10
Atara Biotherapeutics
ATRA
$84.6M
| $8.94M | 2.26% | 434,812 +219,000 | +101% | +$4.5M |
|
|
ATYR
11
aTyr Pharma
ATYR
$527M
| $8.02M | 2.03% | 2,292,659 +1,315,673 | +135% | +$4.6M |
|
|
12
Tempest Therapeutics
TPST
$44M
| $6.57M | 1.66% | +3,512,332 | New | +$6.57M |
|
|
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $5.68M | 1.44% | +258,457 | New | +$5.68M |
|
14
Xencor
XNCR
$580M
| $5.62M | 1.42% | 234,813 -140,187 | -37% | -$3.35M |
|
|
KIN
15
DELISTED
Kindred Biosciences, Inc.
KIN
| $3.84M | 0.97% | 544,880 -26,246 | -5% | -$185K |
|
|
NBRV
16
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $3.18M | 0.8% | 264,773 | – | – |
|
|
RGLS
17
DELISTED
Regulus Therapeutics
RGLS
| $2.49M | 0.63% | +1,510,000 | New | +$2.49M |
|
18
Adverum Biotechnologies
ADVM
$64.6M
| $2.36M | 0.6% | 874,447 | – | – |
|
|
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
| $2.14M | 0.54% | +100,000 | New | +$2.14M |
|
|
VIVE
20
DELISTED
VIVEVE MED INC
VIVE
| $1.58M | 0.4% | +250,000 | New | +$1.58M |
|
21
Agios Pharmaceuticals
AGIO
$2.19B
| $1.36M | 0.34% | 23,300 | – | – |
|
|
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.3M | 0.33% | +382,000 | New | +$1.3M |
|
|
23
FibroGen
FGEN
$47.8M
| $1.04M | 0.26% | 42,009 -644,175 | -94% | -$15.9M |
|
|
SYRS
24
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.01M | 0.26% | 63,596 | – | – |
|
25
Bristol-Myers Squibb
BMY
$96B
| $928K | 0.23% | 17,060 +8,500 | +99% | +$462K |
|